{"filing":{"accession_number":"0001193125-26-397996","cik":"0001107421","ticker":"TCRT","company_name":"Alaunos Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-18","primary_document":"tcrt-20260918.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526397996/tcrt-20260918.htm"},"events":[{"id":34347,"run_id":31608,"accession_number":"0001193125-26-397996","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Alaunos Therapeutics entered into a securities purchase agreement on September 18, 2026, to sell 380,469 shares of common stock and 386,654 pre-funded warrants at $1.46 per share in a registered direct offering, raising approximately $915,400 to $1.1 million in proceeds for general corporate purposes.","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":38046,"accession_number":"0001193125-26-397996","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Alaunos Therapeutics entered into a securities purchase agreement on September 18, 2026, to sell 380,469 shares of common stock at $1.46 per share and 386,654 pre-funded warrants in a registered direct offering, raising approximately $915,400 in net proceeds. This is a registered direct offering of equity securities to accredited investors—a classic dilutive issuance that increases the share count and dilutes existing shareholders. The filing explicitly discloses the offering structure, pricing, and use of proceeds for general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:34:07.213535+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38047,"accession_number":"0001193125-26-397996","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Alaunos Therapeutics announced a registered direct offering of 380,469 shares of common stock and pre-funded warrants to purchase 386,654 shares at $1.46 per share for approximately $1.1 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors priced at-the-market under Nasdaq rules, materially diluting existing shareholders and raising capital for general working capital purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:34:07.213535+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38046,"accession_number":"0001193125-26-397996","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Alaunos Therapeutics entered into a securities purchase agreement on September 18, 2026, to sell 380,469 shares of common stock at $1.46 per share and 386,654 pre-funded warrants in a registered direct offering, raising approximately $915,400 in net proceeds. This is a registered direct offering of equity securities to accredited investors—a classic dilutive issuance that increases the share count and dilutes existing shareholders. The filing explicitly discloses the offering structure, pricing, and use of proceeds for general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:34:07.213535+00:00","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-09-22"},{"id":38047,"accession_number":"0001193125-26-397996","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Alaunos Therapeutics announced a registered direct offering of 380,469 shares of common stock and pre-funded warrants to purchase 386,654 shares at $1.46 per share for approximately $1.1 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors priced at-the-market under Nasdaq rules, materially diluting existing shareholders and raising capital for general working capital purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:34:07.213535+00:00","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-09-22"}]}